Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fc-activating receptors are cell-surface immune receptors that bind the Fc region of immunoglobulins (antibodies), especially IgG (via Fc gamma receptors). These activating Fc receptors (for example, FcγRI, FcγRIIA, FcγRIIIA, FcεRI) are expressed on multiple immune cells including macrophages, neutrophils, NK cells, and dendritic cells. Upon binding antibodies—especially when clustered by immune complexes—they trigger cellular activation via immunoreceptor tyrosine-based activation motifs (ITAMs), leading to diverse effector functions such as phagocytosis, ADCC, cytokine release, and degranulation. Clinically, engaging activating Fc receptors is critical for the mechanisms of action of many therapeutic antibodies, and polymorphisms in Fc receptor genes can affect patient outcomes. The term “Fc-activating receptor” does not refer to a single molecule and should be resolved to a specific receptor subtype for precision.
Antibody-dependent cell-mediated cytotoxicity (ADCC); Antibody-dependent cellular phagocytosis (ADCP); Modulation of inflammatory signaling via FcR crosslinking
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fc-activating receptor.